Zobrazeno 1 - 10
of 113
pro vyhledávání: ''
Autor:
Lei Bi, Fuqiong Zhou, Peng Meng, Bo Tang, Yidan Ren, Yunshan Wang, Yu-Cui Jiang, Weiping Chen, Qin Wang, Chuanxin Wang, Maoxiao Feng, Yuli Wang, Feiyan Chen, Qinlian Jiao, Lutao Du
Publikováno v:
Cancer Research. 81:2015-2028
Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) mediates diverse immune functions and metabolism, yet little is known about
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Jamie J. Shah, Francis Y. Lee, Bruce S. Fischer, Hossein Khiabanian, Sharon R. Pine, Joseph R. Bertino, Katherine M. Morgan, Amartya Singh, Jeffrey A. Rosenfeld
Publikováno v:
Molecular Cancer Therapeutics. 16:2759-2769
Notch signaling is aberrantly activated in approximately one third of non–small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in pr
Autor:
Amit Aggarwal, Gregory P. Donoho, Gregory D. Plowman, Ramon V. Tiu, Robert D. Van Horn, Sheng Bin Peng, Youyan Zhang, Jason C. Ting, Ruslan D. Novosiadly, Yue Webster, Yung Mae M. Yao, Amelie Forest, Philip W. Iversen, Henry James Robert, Philip J. Ebert, Steven M. Bray
Publikováno v:
Clinical Cancer Research. 23:5547-5560
Purpose: To evaluate the antitumor efficacy of cetuximab in combination with LSN3074753, an analog of LY3009120 and pan-RAF inhibitor in 79 colorectal cancer patient-derived xenograft (PDX) models. Experimental Design: Seventy-nine well-characterized
Autor:
Levi Sokol, Kim M. Hirshfield, Chandrika Jeyamohan, Srilatha Simhadri, Janice M. Mehnert, Lorna Rodriguez-Rodriguez, Husam Al-Hraishawi, Shridar Ganesan, Sharon R. Pine, Atul Kulkarni, Suzie Chen, Man Lung Teo, Eileen White, Siraj M. Ali
Publikováno v:
Clinical Cancer Research. 23:5631-5638
Purpose: Many patients with BRAFV600E mutant melanoma treated with BRAF inhibitors experience a rapid response, but ultimately develop resistance. Insight into the mechanism of resistance is critical for development of more effective treatment strate
Autor:
Timothy P. Heffernan, Annette Machado, Ulrich Duenzinger, Joseph R. Marszalek, Christopher P. Vellano, Michael Gmachl, Mark Petronczki, Dorothea Rudolph, Daniel Gerlach, Marco H. Hofmann, Francesca Trapani, Vitomir Vucenovic, Norbert Kraut, Marcelo Marotti, Joseph R. Daniele, Irene Waizenegger, Hengyu Lu
Publikováno v:
Cancer Research. 81:CT210-CT210
The SOS1i::KRAS inhibitor BI 1701963 is the first direct RAS signaling modifier to enter phase I clinical trials both as a monotherapy as well as in combination. SOS1::KRAS inhibitors exhibit activity against a broad spectrum of KRAS alleles, includi
Publikováno v:
Cancer Research. 81:2361-2361
Background: Patients with BRAF-mutated colorectal cancer (CRC) have a poor prognosis despite recent therapeutic advances such as combination therapy with BRAF, MEK, and EGFR inhibitors. Aim: Our aim was to clarify the functions of the microRNAs (miRN
Autor:
Vishnu C. Damalanka, James W. Janetka, Lidija Klampfer, Robert J. Coffey, Galina Bogatcheva, Ramona Graves-Deal, Bhuminder Singh
Publikováno v:
Cancer Research. 81:1084-1084
Using a novel 3D culture system, we previously showed that activation of receptor tyrosine kinases (RTKs) MET and RON contributed to cetuximab resistance in colorectal cancer (CRC) cells. CC derived from HCA-7 cells were sensitive to cetuximab, where
Autor:
Byung-Gyu Kim, Hye Jin Ham, Jung-Guk Kim, Ji-Hyun Kim, Soo-Young Park, Keun-Gyu Park, Jung Yi Lee, Yeon-Kyung Choi, Se Young Jang, Mi Jin Kim, Hui-Jeon Jeon, Inkyu Lee
Publikováno v:
Molecular Cancer Research. 15:1230-1242
The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high. Here, we report metabolic reprogramming in sorafenib-resistant
Autor:
Chun Gong, Fei-jiao Ge, Ming Ni, Jianming Xu, Rongrui Liu, Chuanhua Zhao, Jun-Yan Gu, Yan Wang, Zhaoli Tan, Ru Jia, Mansheng Li, Shuji Ogino, He-Fei Wang, Yang Jin, Yunping Zhu, Li Lin, Youliang Wang, Yu Ling Chen, Tao Liu, Zhi Rong Qian
Publikováno v:
Clinical Cancer Research. 23:4602-4616
Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of